PODD241220C125000
- 86.40
- 0.000.00%
Insulet Newsroom
Leerink Partners Keeps Their Buy Rating on Insulet (PODD)
CCORF Maintains Insulet(PODD.US) With Buy Rating, Maintains Target Price $269
Insulet's Strategic Advancements and Market Positioning Drive Buy Rating
Morgan Stanley Maintains Insulet(PODD.US) With Buy Rating, Raises Target Price to $317
Morgan Stanley Maintains Overweight on Insulet, Raises Price Target to $317
Barclays Sticks to Its Hold Rating for Insulet (PODD)
Insulet's Strong Market Position and Growth Potential Justifies Buy Rating
Analysts Are Bullish on These Healthcare Stocks: Insulet (PODD), Genfit (GNFTF)
A Quick Look at Today's Ratings for Insulet(PODD.US), With a Forecast Between $245 to $300
Wells Fargo Maintains Insulet(PODD.US) With Buy Rating, Raises Target Price to $290
TD Cowen Maintains Insulet(PODD.US) With Buy Rating, Maintains Target Price $264
Insulet's Strong Market Performance and Growth Justify Buy Rating
Insulet Analyst Ratings
Bernstein Initiates Insulet(PODD.US) With Buy Rating, Announces Target Price $300
Insulet Is Maintained at Outperform by Raymond James
Insulet Analyst Ratings
Raymond James Maintains Insulet(PODD.US) With Buy Rating, Raises Target Price to $260
BTIG Maintains Insulet(PODD.US) With Buy Rating, Raises Target Price to $260
Baird Maintains Insulet(PODD.US) With Buy Rating, Raises Target Price to $280
Citi Maintains Insulet(PODD.US) With Buy Rating, Raises Target Price to $275